COMMUNIQUÉS West-GlobeNewswire

Comprehensive Healthcare Welcomes Community Behavioral Health Veteran as Chief Medical Officer
07/01/2026
YAKIMA, Wash., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Comprehensive Healthcare, the leading community behavioral health provider in Central and Southwest Washington, is proud to welcome Mark Bradshaw, M.D., as its new chief [...]
AB Science annonce un quatrième cas consécutif de réponse avec la combinaison d’AB8939 et du venetoclax dans le traitement de la leucémie myéloïde aiguë réfractaire ou en rechute, sur la base des données de phase 1
07/01/2026
COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE UN QUATRIÈME CAS CONSÉCUTIF DE RÉPONSE AVEC LA COMBINAISON D’AB8939 ET DU VENETOCLAX DANS LE TRAITEMENT DE LA LEUCÉMIE MYÉLOÏDE AIGUË RÉFRACTAIRE OU EN RECHUTE, SUR LA BASE DES [...]
AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia
07/01/2026
PRESS RELEASE AB SCIENCE REPORTS FOURTH CONSECUTIVE CASE OF RESPONSE FROM PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA The combination [...]
300 Exceptional Teen Scientists Recognized for Innovative STEM Research in Nation’s Oldest and Most Prestigious High School Competition
07/01/2026
Regeneron Science Talent Search Marks Milestone 85th Year with $1.2 Million Awarded to Nation’s Most Promising Young Scientists and Their Schools WASHINGTON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Society for Science (the [...]
Ipsen - Décembre 2025 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
07/01/2026
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]
Ipsen - December 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
07/01/2026
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]
Herantis Pharma - Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson's disease
07/01/2026
Herantis Pharma Plc – Company release Inside information: Herantis Pharma – Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson's disease Biomarker data show that HER- [...]
Ottimo Pharma Announces FDA Clearance of Investigational New Drug (IND) Application for OTP-01, a First-in-Class, Dual-Paratopic, Single-Agent, Anti-PD-1/VEGFR2 Antibody
07/01/2026
First patient dosed and study open in leading oncology centers in US and Australia Phase I/IIA adaptive study aims to assess and optimize the dose of OTP-01 and provide safety, tolerability, and early efficacy data [...]
Koelis Announces Designated CPT I Codes for Fusion Biopsy and Transperineal Biopsy in Prostate Cancer Diagnosis
07/01/2026
GRENOBLE, France and PRINCETON, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Koelis, SAS (“Koelis” or the “Company”, www.koelis.com ), a leader and innovator in MRI-ultrasound fusion guidance for prostate cancer [...]
HyperCharge Health issues new statement calling for increased attention on Minnesota's Lyme Disease Crisis
07/01/2026
MINNEAPOLIS, Jan. 07, 2026 (GLOBE NEWSWIRE) -- HyperCharge Health is calling on media outlets to help shine a light on this overlooked public health issue and amplify the voices of patients who have gone unheard for far [...]
Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support
07/01/2026
NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that [...]
Recludix Pharma to Present at the Annual J.P. Morgan Healthcare Conference
07/01/2026
SAN DIEGO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced that Nancy [...]
Pacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conferences
07/01/2026
BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, [...]
Science 37 Named Finalist in Two Categories for the 2026 SCOPE Awards
07/01/2026
MORRISVILLE, N.C., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Science 37 , the leader in expanding patient access to clinical trials, today announced it has been named a finalist for two prestigious SCOPE Awards: the Participant [...]
Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
07/01/2026
CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of [...]
Vaxxas Appoints Former Merck Global Vaccines President David Peacock as CEO
07/01/2026
BRISBANE, Australia and CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Vaxxas Pty Ltd today announced the appointment of global biopharmaceutical executive Mr David Peacock as Chief Executive Officer to lead the [...]
ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus
07/01/2026
Conference Call Scheduled for Friday, January 9, 2026 at 9:00 AM ET PORTLAND, Maine, Jan. 07, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that [...]
SeaStar Medical Announces 2026 Milestones
07/01/2026
Drive adoption of QUELIMMUNE for ultra-rare pediatric AKI, expanding revenue and doubling the customer base Advance SeaStar Medical’s first-in-class SCD therapy for the adult AKI indication – a potential $4.5 billion [...]
Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108
07/01/2026
PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing significant unmet needs in ulcerative colitis (UC) and fibrostenotic Crohn’s [...]

Pages